Molecular oncology: Diagnostic and prognostic assessment of human cancers in the clinical laboratory

Cancer Investigation

Volumn 16, Issue 7, 1998, Pages 485-502

  Tsongalis, Gregory J ^a   Coleman, William B ^b  

^a HARTFORD HOSPITAL   (United States)

^b UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DNA; MESSENGER RNA; NUCLEIC ACID; RNA;

ARTICLE; BREAST CANCER; CANCER DIAGNOSIS; CLINICAL LABORATORY; EWING SARCOMA; FAMILIAL CANCER; GENE MUTATION; GENETIC COUNSELING; GENETIC DISORDER; HUMAN; LABORATORY DIAGNOSIS; NEUROBLASTOMA; PRIORITY JOURNAL; PROGNOSIS; PROTO ONCOGENE; TUMOR SUPPRESSOR GENE;

EID: 0031718926     PISSN: 07357907     EISSN: None     Source Type: Journal    
DOI: 10.3109/07357909809011703     Document Type: Article

References (104)

1. Coleman WB, Tsongalis GJ: Molecular mutations in human neoplastic disease: application of nucleic acid technology in the assessment of familial risk, diagnosis, and prognosis of human cancers. In: Molecular Diagnostics: For the Clinical Laboratorian, edited by WB Coleman, GJ Tsongalis, Totowa, NJ, Humana Press, 1997, pp. 293-316.
2. Tsongalis GJ: An overview of medical genetics. In: Molecular Diagnostics: For the Clinical Laboratorian, edited by WB Coleman, GJ Tsongalis, Totowa, NJ, Humana Press, 1997, pp. 217-228.
3. Tsongalis GJ, Berman MM: Application of forensic identity testing in a clinical setting. Diagn Mol Pathol 6:111-114, 1997.
4. Tsongalis GJ, Anamani DE, Wu AHB: Identification of urine specimen donors by the PM+DQA1 amplification and typing kit. J Forens Sci 41:1031-1034, 1996.
5. Aslanzadeh J: Molecular techniques in laboratory diagnosis of infectious diseases. In: Molecular Diagnostics: For the Clinical Laboratorian, edited by WB Coleman, GJ Tsongalis, Totowa, NJ, Humana Press, 1997, pp. 341-360.
6. Coleman WB, Tsongalis GJ: Multiple mechanisms account for genomic instability and molecular mutation in neoplastic transformation. Clin Chem 41:644-657, 1995.
7. Rezuke WN, Abernathy EC, Tsongalis GJ: Molecular diagnosis of B and T cell lymphomas: fundamental principles and clinical applications. Clin Chem 43:1814-1823, 1997.
8. Rezuke WN, Abernathy EC: Molecular genetics and the diagnosis of hematological malignancies. In: Molecular Diagnostics: For the Clinical Laboratorian, edited by WB Coleman, GJ Tsongalis, Totowa, NJ, Humana Press, 1997, pp. 317-339.
9. Foulds L: The natural history of cancer. J Chronic Dis 8:2-37, 1958.
10. Nowell P: The clonal evolution of tumor cell populations. Science 194:23-38, 1976.
11. Weinberg RA: Oncogenes, antioncogenes, and the molecular bases of multistep carcinogenesis. Cancer Res 49:3713-3721, 1989.
12. Bishop JM: Molecular themes in oncogenesis. Cell 64:235-248, 1991.
13. Renan MJ: How many mutations are required for tumorigenesis? Implications from human cancer data. Mol Carcinogen 7: 139-146, 1993.
14. Loeb LA, Christians FC: Multiple mutations in human cancers. Mutat Res 350:279-286, 1996.
15. Sugarbaker, JP, Gunderson, LL, Wittes. RE: Colorectal cancer. In: Cancer: Principles and Practice of Oncology, edited by VT De Vita Jr, S Hellman, SA Rosenberg, Philadelphia, J.B. Lippincott, 1985.
16. Cohen AM, Minsky BD, Schilsky RL: Cancer of the colon. In: Cancer: Principles and Practice of Oncology, 5th edition, edited by VT De Vita Jr, S Hellman, SA Rosenberg, Philadelphia, Lippincott-Raven, 1997.
17. Chabner BA, Haluska FG, Talcott JA: Screening strategies for cancer. JAMA 277:1475-1476, 1997.
18. Livingston DM: Genetics is coming to oncology. JAMA 277: 1476-1477, 1997.
19. Geller G, Botkin JR, Green MJ, et al: Genetic testing for susceptibility to adult-onset cancer. JAMA 277:1467-1474, 1997.
20. Sidransky D: Molecular screening-How long can we afford to wait? J Natl Cancer Inst 86:955-956, 1994.
21. Mao L, Sidransky D: Cancer screening based on genetic alterations in human tumors. Cancer Res 54:1939S-1940S, 1994.
22. Sidransky D: Molecular markers in cancer: Can we make better predictions? Int J Cancer 64:1-2, 1995.
23. Anderson MW, Reynolds SH, You M, et al: Role of proto-oncogene activation in carcinogenesis. Environ Health Perspect 98: 13-24, 1992.
24. Cooper GM. Oncogenes, 2nd edition, Boston, Jones and Bartlett Publishers, 1995.
25. Marshall CJ: Tumor suppressor genes. Cell 64:313-326, 1991.
26. Friend S: p53: a glimpse at the puppet behind the shadow play. Science 265:334-335, 1994.
27. Levine, AJ: p53, the cellular gatekeeper for growth and division. Cell 88:323-331, 1997.
28. Paulovich AG, Toczyski DP, Hartwell LH: When checkpoints fail. Cell 88:315-321, 1997.
29. Hartwell LH, Weinert TA: Checkpoints: controls that ensure the order of cell cycle events. Science 246:629-634, 1989.
30. Hartwell L: Defects in a cell cycle checkpoint may be responsible for the genomic instability of cancer cells. Cell 71:543-546, 1992.
31. 1 cyclins and control of the cell division cycle in normal and transformed cells. Cancer Invest 15:143-152, 1997.
32. Sancar A, Sancar GB: DNA repair enzymes. Ann Rev Biochem 57:29-67, 1988.
33. Kaufmann WK: Pathways of human cell postreplication repair. Carcinogenesis 10:1-11, 1989.
34. Naegeli H: Mechanisms of DNA damage recognition in mammalian nucleotide excision repair. FASEB J 9:1043-1050, 1995.
35. Eshleman JR, Markowitz, SD: Mismatch repair defects in human carcinogenesis. Hum Mol Genet 5:1489-1494, 1996.
36. Umar, A, Kunkel TA: DNA-replication fidelity, mismatch repair and genome instability in cancer cells. Eur J Biochem 238:297-307, 1996.
37. Cohen SM, Ellwein LB: Genetic errors, cell proliferation, and carcinogenesis. Cancer Res 51:6493-6505, 1991.
38. Cohen SM, Ellwein LB: Cell proliferation in carcinogenesis. Science 249:1007-1011, 1990.
39. Hunter T: Oncoprotein networks. Cell 88:333-346, 1997.
40. Zambetti GP, Levine AJ: A comparison of the biological activities of wild-type and mutant p53. FASEB J 7:855-865, 1993.
41. Milner J: Forms and functions of p53. Semin Cancer Biol 5: 211-219, 1994.
42. Hollingsworth RE, Hensely CE, Lee WH: Retinoblastoma protein and the cell cycle. Curr Opin Genet Develop 3:55-62, 1993.
43. Perry ME, Levine AJ: Tumor-suppressor p53 and the cell cycle. Curr Opin Genet Develop 3:50-54, 1993.
44. Bos JL: ras oncogenes in human cancer: a review. Cancer Res 49:4682-4689, 1989.
45. Hollstein M, Sidransky D, Vogelstein B, et al: p53 mutations in human cancers. Science 253:49-53, 1991.
46. Greenblatt MS, Bennett WP, Hollstein M, et al: Mutations in the p53 tumor suppressor gene: clues to cancer etiology and molecular pathogenesis. Cancer Res 54:4855-4878, 1994.
47. Pines J: Cyclins and their associated cyclin-dependent kinases in the human cell cycle. Biochem Soc Trans 21:921-925, 1993.
48. Cordon-Cardo C: Mutation of cell cycle regulators. Biological and clinical implications for human neoplasia. Am J Pathol 147: 454-560, 1995.
49. Spitz MR, Bondy ML: Genetic susceptibility to cancer. Cancer 72:991-995, 1993.
50. Friedberg EC, DNA Repair. New York, W.H. Freeman, 1985.
51. Weeda G, Hoeijmakers JHJ, Bootsma D: Genes controlling nucleotide excision repair in eukaryotic cells. BioEssays 15:249-258, 1993.
52. Sancar A: Mechanisms of DNA excision repair. Science 266: 1954-1956, 1994.
53. Bhagwat AS: Restriction enzymes: properties and use. Methods Enzymol 216:199-224, 1992.
54. McClelland M, Nelson M: The effect of site-specific DNA methylation on restriction endonucleases and DNA modification methyltranbsferases - a review. Gene 74:291-304, 1988.
55. Sambrook J, Fritsch EF, Maniatis T. Molecular Cloning: A Laboratory Manual. Second Edition. Cold Spring Harbor, NY, Cold Spring Harbor Laboratory Press, 1989.
56. Harwood AJ. Basic DNA and RNA Protocols. Totowa, NJ, Humana Press, 1996.
57. Southern EM: Detection of specific sequences among DNA fragments separated by gel electrophoresis. J Mol Biol 98:503-517, 1975.
58. Presnell SC: Nucleic acid blotting techniques: theory and practice. In: Molecular Diagnostics: For the Clinical Laboratorian, edited by WB Coleman, GJ Tsongalis, Totowa, NJ, Humana Press, 1997, pp. 63-87.
59. Feinberg AP, Vogelstein B: A technique for radiolabelling DNA restriction endonuclease fragments to high specific activity. Anal Biochem 132:6-13, 1983.
60. Feinberg AP, Vogelstein B: Addendum: a technique for radiolabelling DNA restriction endonuclease fragments to high specific activity. Anal Biochem 137:266-267, 1984.
61. Rigby PWJ, Dieckmann M, Rhodes C, et al: Labeling deoxyribonucleic acid to high specific activity in vitro by nick translation with DNA polymerase I. J Mol Biol 113:237-251, 1977.
62. Saiki RK, Scharf S, Faloona F, et al: Enzymatic amplification of (-globin genomic sequences and restriction site analysis of sickle cell anemia. Science 230:1350-1354, 1985.
63. Mullis KB, Faloona FA: Specific synthesis of DNA in vitro via a polymerase-catalyzed chain reaction. Methods Enzymol 155: 335-350, 1987.
64. Saiki RK, Gelfand DH, Stoffel S, et al: Primer-directed enzymatic amplification of DNA with a thermostable DNA polymerase. Science 239:487-491, 1988.
65. Sorscher DH: DNA amplification techniques: an overview. In: Molecular Diagnostics: For the Clinical Laboratorian, edited by WB Coleman, GJ Tsongalis, Totowa, NJ, Humana Press, 1997, pp. 89-101.
66. Cheng S, Fockler C, Barnes WM, et al: Effective amplification of long targets from cloned inserts and human genomic DNA. Proc Natl Acad Sci USA 91:5695-5699, 1994.
67. Rohlfs EM, Highsmith WE: PCR-based methods for mutation detection. In: Molecular Diagnostics: For the Clinical Laboratorian, edited by WB Coleman, GJ Tsongalis, Totowa, NJ, Humana Press, 1997, pp. 123-162.
68. Du Z, Hood L, Wilson RK: Automated fluorescent DNA sequencing of polymerase chain reaction products. Methods Enzymol 218:104-121, 1993.
69. Frohman MA: Cloning PCR products. In: The Polymerase Chain Reaction, edited by KB Mullis, F Ferre, RA Gibbs, Boston, Birkhauser, 1994, pp. 14-37.
70. Orita M, Suzuki Y, Sekiya T, et al: Rapid and sensitive detection of point mutations and DNA polymorphisms using the polymerase chain reaction. Genomics 5:874-879, 1989.
71. Myers RM, Lumelsky N, Lerman LS, et al: Detection of single base substitutions in total genomic DNA. Nature 313:495-498, 1985.
72. Bhattacharyya A, Lilley DMJ: The contrasting structures of mismatched DNA sequences containing looped-out bases (bulges) and multiple mismatches (bubbles). Nucleic Acids Res 17:6821-6840, 1989.
73. Ferre F, Marchese A, Pezzoli P, et al: Quantitative PCR: an overview. In: The Polymerase Chain Reaction, edited by KB Mullis, F Ferre, RA Gibbs, Boston, Birkhauser, 1994, pp. 67-88.
74. Chelly J, Kahn A: RT-PCR and mRNA quantitation. In: The Polymerase Chain Reaction, edited by KB Mullis, F Ferre, RA Gibbs, Boston, Birkhauser, 1994, pp. 97-109.
75. Maxam AM, Gilbert W: Sequencing end-labeled DNA with base-specific chemical cleavages. Methods Enzymol 65:499-560, 1980.
76. Sanger F, Nicklen S, Coulson AR: DNA sequencing with chain-terminating inhibitors. Proc Natl Acad Sci USA 74:5463-5467, 1977.
77. Smith LM, Sanders JZ, Kaiser RJ, et al: Fluorescence detection in automated DNA sequence analysis. Nature 321:674-679, 1986.
78. Ansorge W, Sproat BS, Stegemann J, et al: A non-radioactive automated method for DNA sequence determination. J Biochem Biophys Methods 13:315-23, 1986.
79. Highsmith WE, Silverman L: Evolution of automated molecular diagnostics. Clin Chem 9:1367-1368, 1996.
80. Joshi VV, Tsongalis GJ: Correlation between morphologic and nonmorphologic prognostic markers of neuroblastoma. Annals NY Acad Sci 824:71-83, 1997.
81. Seeger RC, Brodeur GM, Sather H, et al: Association of multiple copies of the N-myc oncogene with rapid progression of neuroblastomas. N Engl J Med 313:1111-1116, 1985.
82. Crabbe DCG, Peters J, Seeger RC: Rapid detection of MYCN gene amplification in neuroblastomas using the polymerase chain reaction. Diagn Mol Pathol 1(4):229-234, 1992.
83. Frye RA, Benz CC, Liu E: Detection of amplified oncogenes by differential polymerase chain reaction. Oncogene 4:1153-1157, 1989.
84. Gilbert J, Norris MD, Haber M, et al: Determination of N-myc gene amplification in neuroblastoma by differential polymerase chain reaction. Molec Cell Probes 7:227-234, 1993.
85. Boerner S, Squire J, Thorner P, et al: Assessment of MYCN amplification in neuroblastoma biopsies by differential polymerase chain reaction. Pediatr Pathol 14:823-832, 1994.
86. Waha A, Rollbrocker B, Wiestler OD, et al: A polymerase chain reactio-based assay for the rapid detection of gene amplification in human tumors. Diagn Mol Pathol 5(2):147-150, 1996.
87. Zoubek A, Dockhorn-Dworniczak B, Delattre O, et al: Does expression of different EWS chimeric transcripts define clinically distinct risk groups of Ewing tumor patients. J Clin Oncol 14: 1245-1251, 1996.
88. Sorensen PHB, Liu XF, Delattre O, et al: Reverse transcriptase PCR amplification of EWS/FLI-1 fusion transcripts as a diagnsotic test for peripheral primitive neuroectodermal tumors of childhood. Diagn Mol Pathol 2(3):147-157, 1993.
89. Thorner P, Squire J, Chilton-MacNeill, et al: Is the EWS/FLI-1 fusion transcript specific for Ewing sarcoma and peripheral primitive neuroectodermal tumor. Am J Pathol 148:1125-1138, 1996.
90. Delattre O, Zucman J, Melot T, et al: The Ewing family of tumors: a subgroup of small round-cell tumors defined by specific chimeric transcripts. N Engl J Med 331:294-299, 1994.
91. Zoubek A, Pfleiderer C, Salzer-Kuntschik M, et al: Variability of EWS chimaeric transcripts in Ewing tumors: a comparison of clinical and molecular data. Br J Cancer 70:908-913, 1994.
92. Parker SL, Tong T, Bolden S, et al: Cancer statistics, 1997. CA: Cancer J Clin 47:5-27, 1997.
93. Mandavilli SR, Cartun RW, Ricci Jr A, et al: Immunohistochemical evaluation of genetic and epigenetic factors in primary breast cancers. J Histotechnol 20:27-30, 1997.
94. Marcus JN, Watson P, Page DL, et al: Herediatry breast cancer. Cancer 77:697-709, 1996.
95. Gayther Sa, Ponder BAJ: Mutations of the BRCA1 and BRCA2 genes and the possibilities for predictive testing. Molec Med Today 3:168-174, 1997.
96. Oddoux C, Struewing JP, Clayton CM, et al: The carrier frequency of the BRCA1 6174delT mutation among Ashkenazi Jewish individuals is approximately 1%. Nat Genet 14:188-190, 1996.
97. Tavtigian SV, Simard J, Rommens J, et al: The complete BRCA1 gene and mutations in chromosome 13q-linked kindreds. Nat Genet 12:333-337, 1996.
98. Couch FJ, Weber BL: Breast Cancer Information Core: mutations and polymorphisms in the familial early-onset breast cancer (BRCA1) gene. Hum Mutat 8:8-18, 1996.
99. Tonin P, Weber B, Offit K, et al: Frequency of recurrent BRCA1 and BRCA2 mutations in Ashkenazi Jewish breast cancer families. Nat Med 2:1179-1183, 1996.
100. Rohlfs EM, Learning WG, Friedman KJ, et al: Direct detection of mutations in the breast and ovarian cancer susceptibility gene BRCA1 by PCR-mediated site-directed mutagenesis. Clin Chem 43:24-29, 1997.
101. Offit K, Gilewski T, McGuire P, et al: Germline BRCA1 185de-lAG mutations in Jewish women with breast cancer. Lancet 347: 1643-1645, 1996.
102. Roa BB, Boyd AA, Volcik K, et al: Ashkenazi Jewish population frequencies for common mutations in BRCA1 and BRCA2. Nat Genet 14:185-187, 1996.
103. Haliassos A, Chomel JC, Tesson L, et al: Modification of enzymatically amplified DNA for the detection of point mutations. Nucleic Acid Res 17:3606-3610, 1989.
104. Burke W, Daly M, Garber J, et al: Recommendations for follow-up care of individuals with an inherited predisposition to cancer: BRCA1 and BRCA2. JAMA 277:997-1003, 1997.